Last reviewed 2026-04-22 · How we verify

Sirolimus+MMF or MPS or AZA+Steroid

This combination regimen suppresses T-cell proliferation and antibody production through mTOR inhibition (sirolimus) and inosine monophosphate dehydrogenase inhibition (MMF/MPS/AZA), used to prevent organ rejection.

This combination regimen suppresses T-cell proliferation and antibody production through mTOR inhibition (sirolimus) and inosine monophosphate dehydrogenase inhibition (MMF/MPS/AZA), used to prevent organ rejection. Used for Prevention of organ rejection in solid organ transplantation (kidney, heart, liver), Chronic rejection prevention in transplant recipients.

At a glance

Mechanism of action

Sirolimus is an mTOR inhibitor that blocks T-cell and B-cell proliferation by preventing cell cycle progression. MMF (mycophenolate mofetil), MPS (mycophenolate sodium), or AZA (azathioprine) inhibit purine synthesis preferentially in lymphocytes. Corticosteroids provide additional immunosuppression through multiple mechanisms. Together, this triple therapy provides potent immunosuppression for transplant rejection prevention.

Approved indications

• Prevention of organ rejection in solid organ transplantation (kidney, heart, liver)
• Chronic rejection prevention in transplant recipients

Common side effects

• Infection (bacterial, viral, fungal)
• Anemia
• Thrombocytopenia
• Gastrointestinal disturbances
• Hyperlipidemia
• Hyperglycemia
• Hypertension
• Nephrotoxicity

Key clinical trials

• Study Evaluating of Calcineurin Inhibitors Versus Sirolimus in Renal Allograft Recipient (PHASE4)
• Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.